Privacy Policy
Signals Blog

Contributors

Categories

Sticky cells are the key to printing 3D organs

. It’s been about 50 years since Philip K. Dick, one of the greatest science fiction authors, introduced the idea of artificial organs replacing failing or diseased organs. In his novel, Ubik, the author writes: “[Glen] Runciter’s body contained a dozen...

Right Turn: Back soon!

.   I hope the last two weeks of Right Turn made you smile while I was on vacation. I expect I’ll be back on the job next week feeling refreshed and rejuvenated, or I might be completely overwhelmed due to post-vacation workload. Still, it was worth it. Thanks...

Right Turn: Great tweets of science

. I’m still on vacation, but I’m thinking about you loyal readers. I hope this clever list of tweets, from PhD Comics, gives you a chuckle. If you’re feeling creative, please add some additional “great tweets of science” in the comments below.   Our regular...

Stem cells: like mother, like daughter

. If you’re a frequent reader of Signals, you’ve probably seen the phrase “self-renewal” at least once. And if you’re anything like me, you’re probably still a bit confused as to what it means. Yes, I admit it, even after being a part of the cancer stem cell field for...

Right Turn: Vacation Relaxation

. I knew I was going to miss my co-editor, Lisa Willemse, but never more so than now, as I contemplate producing content for Signals during my three-week (spoiled, I know) vacation. The empathetic minds behind PhD Comics have neatly summed up my mood right now – and...

Right Turn: Scaling up blood stem cells for transplants

. Cord blood banking is a growing market in North America and globally. Between 2005 and 2013, the number of privately banked units grew steadily at a CAGR (compound annual growth rate) of 25 per cent, giving companies the ability to capitalize on a part of the...

Update from the Clinic: May

. Welcome to your Update from the Clinic for the month of May. StemCells announced positive topline results from a Phase I/II study in spinal cord injury. Kite Pharma treated its first patient in a Phase I/II study investigating an anti-CD19 CAR T construct in...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!